RVPH
What one share of Reviva Pharmaceuticals Holdings holds
Pharmaceutical Preparations
On December 14, 2020, our predecessor company, formerly known as Tenzing Acquisition Corp., a British Virgin Islands exempted company (“Tenzing”), and Reviva Pharmaceuticals, Inc., a Delaware corporation (together with its consolidated subsidiaries, “Old Reviva”), consummated the transactions (the “Business Combination”) contemplated by the Agreement and Plan of Merger, dated as of July 20, 2020 (as amended, the “Merger Agreement”), by and among Tenzing, Tenzing Merger…
Reviva Pharmaceuticals Holdings’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.75 |
|---|---|
| Cash and investments | $1.52 |
| Book value | $1.16 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$0.31 | — | −$0.08 | — | — |
| 2020 | — | −$0.21 | — | −$0.16 | — | $1.85 |
| 2020 | — | −$1.24 | — | −$1.33 | — | — |
| 2021 | — | −$0.58 | — | −$0.72 | — | $1.99 |
| 2022 | — | −$1.45 | — | −$0.97 | — | $0.41 |
| 2023 | — | −$1.65 | — | −$1.19 | — | $0.20 |
| 2024 | — | −$17.73 | — | −$19.88 | — | $0.34 |
| 2025 | — | −$5.48 | — | −$6.78 | — | $1.47 |